Menu
Not yet recruiting NCT05626465

Biomarker-s of Abusive Head Trauma by Proteomics

Observational Abuse, Child Protein Disorder, Blood

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Blood test.
Who it may be relevant to
Registry conditions: Abuse, Child, Protein Disorder, Blood. Basic parameters: up to 2 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France, Switzerland
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Identification of Novel Biomarker-s of Abusive Head Trauma on Serum by Proteomics

Overview

The aim of our study is to highlight biomarker-s of Abusive Head Trauma by proteomics analyses on the serum of child victims of abuse.

Interventions

  • Other Blood test
    Proteomic analyses on serum

Primary outcome measures

  • Highlight novel biomarker-s of AHT [Time frame: Hospital admission to discharge (up to 3 days)]

Eligibility criteria

Inclusion criteria

  • Age : 0-2 y.o
  • Medical consultation for malaise, seizure (without fever), loss of consciousness, traumatic bain injury, or cranioplasty
  • Blood test during medical care
  • Accepted informed consent

Exclusion criteria

  • Refused informed consent
  • For control groups : medical history of child abuse
  • For AHT group : rare metabolic disease (Menkes, etc..)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Case-control

Study locations

France · 1 center
  • Ginhoux Thiphanie — Lyon
Switzerland · 1 center
  • Wiskott Kim — Geneva

Identifiers

NCT: NCT05626465 · 2021-01971

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗